Investors & Media
Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
Clinical data from part 1 of an ongoing, first-in-human, Phase 1, dose escalation study of CYC065 has been selected for oral presentation. Details are as follows:
|Title:||Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)|
|Category:||Phase I Adult Clinical Trials|
|Session:||CTMS01 - New Treatment Approaches for Breast and Ovarian Cancer|
|Location:||Room N427 - McCormick Place North (Level 4)|
|Date and Time:||Sunday, April 15, 2018, 3:00 PM - 5:00 PM|
The abstract is embargoed at this time and will be made available in accordance with AACR rules at http://www.abstractsonline.com/pp8/#!/4562/presentation/11142.
Preclinical data by academic collaborators of the Company evaluating the rationale for potential combination regimens of CYC065 and venetoclax, a Bcl-2 inhibitor approved for patients with certain chronic lymphocytic leukemias (CLL) under conditions that mimic the lymph node tumor microenvironment, have been selected for a poster presentation. Details are as follows:
|Title:||Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia|
|Category:||Experimental and Molecular Therapeutics|
|Session:||PO.ET07.03 - Receptor Targeting and the Tumor Microenvironment|
|Abstract #:||3905/ 5|
|Location:||McCormick Place South, Exhibit Hall A, Poster Section 38|
|Date and Time:||Tuesday, April 17, 2018, 8:00 AM - 12:00 PM|
The abstract is available at www.abstractsonline.com/pp8/#!/4562/presentation/4821.
CYC065, a second generation CDK2/9 inhibitor, is being evaluated in a first-in-human, Phase 1 trial in patients with advanced solid tumors. It is mechanistically similar but has higher dose potency, in vitro and in vivo, and improved properties compared to seliciclib, a first generation CDK inhibitor. Similarly to
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the
|Company:||Paul McBarron, (908) 517-7330, email@example.com|
|Investor Relations:||Russo Partners LLC, Alexander Fudukidis, (646) 942-5632,|
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.